Meeting
2015 ASCO Annual Meeting
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
Authors
Hui K. Gan
Austin Health and Ludwig Institute for Cancer Research, Melbourne, Australia
Hui K. Gan , Kyriakos P. Papadopoulos , Lisa Fichtel , Andrew B. Lassman , Ryan Merrell , Martin J. Van Den Bent , Priya Kumthekar , Andrew M. Scott , Michelle Pedersen , Erica J. Gomez , Judee S. Fischer , William Ames , Hao Xiong , Ho-Jin Lee , Wijith Munasinghe , Lisa Roberts-Rapp , Peter Ansell , Kyle D. Holen , Rose Lai , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01800695
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2016)
DOI
10.1200/jco.2015.33.15_suppl.2016
Abstract #
2016
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
First Author: Hui Kong Gan
Poster
2019 ASCO Annual Meeting
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.
First Author: Jing Wu
Poster
2019 ASCO Annual Meeting
Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.
First Author: Martin Kelly Nicholas
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran